Premium
Carcinoembryonic antigen in breast cancer patients: Serum levels and disease progress
Author(s) -
Steward A. M.,
Nixon D.,
Zamcheck N.,
Aisenberg A.
Publication year - 1974
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197405)33:5<1246::aid-cncr2820330509>3.0.co;2-o
Subject(s) - medicine , carcinoembryonic antigen , breast cancer , disease , cancer , oncology , hormonal therapy , metastatic breast cancer , hormone , breast disease , cancer antigen , gastroenterology
Serum CEA was evaluated in 69 patients with breast cancer and 17 with benign breast disease. Serum CEA was elevated (above 2.5 ng/ml) in 6 of 22 patients (27%) with primary cancer without clinical evidence of distant metastases, and in 37 of the 47 (79%) who had metastatic disease. Sixteen of 17 patients (94%) with benign cystic disease had values less than 2.5 ng/ml (1 was 2.9 ng/ml). Fourteen patients with metastases undergoing chemo‐ and hormonal therapy were studied by serial CEA estimations for 3 to 18 months, with a mean of 14 months. The trends of serial CEA values correlated with response to treatment.